Avapritinib Delivers Durable Survival Gains in Advanced Systemic Mastocytosis Avapritinib produced deep, durable responses in advanced systemic mastocytosis (SM) with a 73% ORR and median OS of 62 months at 4 years.

#Avapritinib produced deep and durable clinical benefit with prolonged survival in patients with #AdvSM, with low rates of disease progression over more than 4 years of follow-up and a favorable benefit-risk profile. @bloodadvances.bsky.social

Read here: https://bit.ly/4tAWezk

Long-Term Avapritinib Use Sustains Responses in Advanced SM Four-year follow-up demonstrated durable survival, sustained responses, and disease control with first-line avapritinib in advanced SM.

#Avapritinib produced durable survival, demonstrated deep molecular and organ responses, and sustained bone benefits as first-line therapy for advanced #SystemicMastocytosis (SM), supporting long-term disease modification across SM subtypes.

Read here: https://bit.ly/49XipaM

#RareDisease #MedSky

Avapritinib Linked to Sustained Improvements in Skin Manifestations of Indolent SM Patients with indolent SM and dermatologic involvement treated with avapritinib saw marked reductions in skin symptoms, skin color, and skin lesions.

In patients with indolent #SystemicMastocytosis (SM), treatment with #Avapritinib has been associated with statistically significant, clinically meaningful improvements in dermatologic manifestations of the disorder. Findings from the #PIONEER trial (#NCT03731260)

Learn more: https://bit.ly/4iqRVS0

Patient With SM Due to Rare KIT Exon 11 Mutation Responds Well to Avapritinib A male child with refractory systemic mastocytosis showed remarkable signs of improvement following avapritinib administration.

A male child with refractory #SystemicMastocytosis (SM) with AML1::ETO+ #AcuteMyeloidLeukemia (AML) showed remarkable signs of improvement following #Avapritinib administration. Case report in Frontier in Pediatrics

Read more: https://bit.ly/3WsYBVx

#RareDisease #SM #AML #Leukemia #MedSky

Blueprint Medicines Presents Long-Term AYVAKIT®/AYVAKYT® Efficacy at Major Congresses Blueprint Medicines showcased significant findings on AYVAKIT®/AYVAKYT® treatment at two major congresses, emphasizing its sustained efficacy and safety profile for systemic mastocytosis.

Blueprint Medicines Presents Long-Term AYVAKIT®/AYVAKYT® Efficacy at Major Congresses #USA #Cambridge #AYVAKIT #Blueprint_Medicines #avapritinib

Blueprint Medicines Achieves Strong Q1 2025 Performance with AYVAKIT Revenue Surge Blueprint Medicines delivers impressive Q1 2025 results, with a significant increase in AYVAKIT revenues and an optimistic financial outlook.

Blueprint Medicines Achieves Strong Q1 2025 Performance with AYVAKIT Revenue Surge #United_States #Cambridge #AYVAKIT #Blueprint_Medicines #avapritinib

CStone Pharmaceuticals Reports 2024 Results and Strategic Developments in Oncology CStone Pharmaceuticals has unveiled robust 2024 annual results, highlighting significant revenue growth and strategic advancements in cancer therapies.

CStone Pharmaceuticals Reports 2024 Results and Strategic Developments in Oncology #China #Suzhou #CStone_Pharmaceuticals #Sugemalimab #avapritinib

Effective targeting of PDGFRA-altered high-grade glioma with avapritinib PDGFRA is commonly altered in pediatric HGG. Mayr et al. report that the PDGFRA/KIT inhibitor avapritinib demonstrates on-target activity, brain penetrance, and survival benefit in pre-clinical H3K27M...

New hope for #BrainTumors in #Children: Research team from #MedUni #Vienna discovers targeted therapy for aggressive gliomas. The #PDGFRA inhibitor #Avapritinib shows initial success – tumors resistant to radiation are responding. Promising! #Cancer
www.cell.com/cancer-cell/...

Effective targeting of PDGFRA-altered high-grade glioma with avapritinib PDGFRA is commonly altered in pediatric HGG. Mayr et al. report that the PDGFRA/KIT inhibitor avapritinib demonstrates on-target activity, brain penetrance, and survival benefit in pre-clinical H3K27M...

Hoffnung bei #Hirntumoren bei #Kindern: Forschungsteam der #MedUni #Wien entdeckt gezielte Therapie gegen aggressive #Gliome. Der #PDGFRA-Inhibitor #Avapritinib zeigt erste Erfolge – Tumore, die resistent gegen Bestrahlung waren, sprechen an. Vielversprechend! #Krebs
www.cell.com/cancer-cell/...